Sleep Cycle AB (publ) (STO:SLEEP)
Sweden · Delayed Price · Currency is SEK | Market Cap | 311.06M -61.2% |
| Revenue (ttm) | 235.96M -10.4% |
| Net Income | 44.92M -30.8% |
| EPS | 2.21 -30.9% |
| Shares Out | 20.28M |
| PE Ratio | 6.94 |
| Forward PE | 26.91 |
| Dividend | 0.53 (3.46%) |
| Ex-Dividend Date | Apr 14, 2026 |
| Volume | 12,044 |
| Average Volume | 22,331 |
| Open | 15.18 |
| Previous Close | 15.34 |
| Day's Range | 15.16 - 15.38 |
| 52-Week Range | 14.84 - 34.70 |
| Beta | -0.01 |
| RSI | 35.23 |
| Earnings Date | Apr 29, 2026 |
About Sleep Cycle AB
Sleep Cycle AB (publ) engages in the development of sleep analysis applications in Sweden and internationally. It offers Sleep Cycle, an application that provides sleep-related solutions, including smart alarm, sleep stages and aid, and sound recordings; and Luma, an AI-driven sleep coach. The company was incorporated in 2001 and is headquartered in Gothenburg, Sweden. [Read more]
Financial Performance
In 2025, Sleep Cycle AB's revenue was 247.88 million, a decrease of -5.22% compared to the previous year's 261.53 million. Earnings were 53.21 million, a decrease of -15.06%.
Financial StatementsNews
Sleep Cycle AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a planned revenue dip as investments shifted toward B2B, sleep apnea, and tech licensing, with B2B revenue up 42% year-over-year and now 15% of total revenue. The business remains profitable, with strong liquidity and a clear path to growth and margin recovery from 2027.
Sleep Cycle AB Earnings Call Transcript: Q4 2025
Net sales declined amid a soft consumer market, but profitability and cash flow remained strong. Rapid B2B growth and MedTech initiatives are driving a strategic transformation, with 2026 set as an investment year and growth expected to resume in 2027.
Sleep Cycle AB Earnings Call Transcript: Q3 2025
Q3 saw revenue decline and subscriber softness, but partnership revenue surged 55% year-over-year, now 11% of total revenue. Price increases and product innovation aim to offset headwinds, while the Powered by Sleep SDK and sleep apnea screening initiative drive future growth.
Sleep Cycle AB Earnings Call Transcript: Q2 2025
Q2 2025 saw a slight decline in subscribers and net sales due to softer D2C market conditions, but partnership revenue grew over 60% year-over-year and now represents nearly 10% of total revenue. Profitability remains strong, and the company is advancing its sleep apnea screening project.
Sleep Cycle AB Earnings Call Transcript: Q1 2025
Net revenue grew 2.3% year-over-year to SEK 64.9 million, with subscriber base up 1.2% but down sequentially. EBIT margin remained strong at 26.3% despite higher marketing costs, and market share increased amid industry headwinds.
Sleep Cycle AB Earnings Call Transcript: Q4 2024
Q4 saw 9% revenue growth and a 32.3% EBIT margin, with subscriber and ARPU increases driven by product innovation and partnerships. The company is investing in medical-grade certification and new revenue streams, while maintaining a strong dividend policy and updated EBIT margin target of at least 25%.
Sleep Cycle AB Earnings Call Transcript: Q3 2024
Subscriber base grew to 915,000, driving 8.4% revenue growth and a 31.3% EBIT margin in Q3. Strategic partnerships and revenue management initiatives supported strong financials, with 2024 EBIT margin now expected at 28%.
Sleep Cycle AB Earnings Call Transcript: Q2 2024
Q2 saw 13% net revenue growth and a 32% EBIT margin, with subscriber numbers and ARPU both rising. Strategic focus remains on user growth, cost control, and new product features, while partnerships and pricing initiatives are expected to drive future gains.